Kiniksa Pharmaceuticals Reports Q3 Earnings Beat with Significant Revenue Growth
Kiniksa Pharmaceuticals International (KNSA) reported third-quarter financial results that exceeded analyst expectations on both the top and bottom lines. The company posted a GAAP earnings per share (EPS) of $0.56, surpassing estimates by $0.21, while revenue reached $286 million, representing a 58.1% increase year-over-year. The strong performance was driven by robust commercial activity, with total revenue beating consensus estimates by approximately $25.39 million. Looking ahead, the company provided updated financial guidance for its key product, ARCALYST, projecting 2026 net product revenue to fall between $1.045 billion and $1.050 billion.
Tickers: $KNSA